Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02395510 · ClinicalTrials.gov registry record · Phase 4
A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder
A Phase 4 study of Panic Disorder, sponsored by Siyan Clinical Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT02395510: Completed Phase 4 study of Panic Disorder, sponsored by Siyan Clinical Corporation.
NCT02395510 is a Phase 4 study of Panic Disorder that has completed, run by Siyan Clinical Corporation. The registered enrollment target is 27 participants, below the 221-participant average among 25 other Panic Disorder trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02395510, a Phase 4 study of Panic Disorder, has completed, sponsored by Siyan Clinical Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this study is to evaluate the efficacy of Vortioxetine in an adult population with a diagnosis of PD. PD is generally treated with benzodiazepines which are very effective but have a high risk for addiction, fall, and cognitive impairment. There is still a need for better treatment for PD for longer term use. There are other drugs within the SSRI/SNRI class which have proven to be effective in treating patients with this diagnosis.
Conditions Studied
Interventions
- DRUG Vortioxetine
Study Locations (1)
California
- Siyan Clinical Corporation - Santa Rosa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-06 |
| Phase | Phase 4 |
What the finished NCT02395510 record still lists
NCT02395510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 221-participant average among 25 other Panic Disorder trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Panic Disorder appearing as the primary indexed condition, and to 1 intervention - of which Vortioxetine is the first listed.
NCT02395510 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02395510 about?
NCT02395510 is a clinical study titled "A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder". The primary aim of this study is to evaluate the efficacy of Vortioxetine in an adult population with a diagnosis of PD. PD is generally treated with benzodiazepines which are very effective but have a high risk for addiction, fall, and cognitive impairment. There is still a need for better treatmen...
What is the current status of trial NCT02395510?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2015-05. Estimated completion is 2016-06.
What conditions does trial NCT02395510 study?
This clinical trial studies the following conditions: Panic Disorder.
What interventions are being tested in trial NCT02395510?
The interventions under investigation include: Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT02395510?
This trial is sponsored by Siyan Clinical Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02395510 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Panic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02395510's enrollment target sits among peer trials
27 23rd of 25 higher than 3 of 25 other Panic Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Panic Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
COMPLETED · Phase 4
-
A Study of Risperidone Monotherapy in Bipolar Anxiety
COMPLETED · Phase 4
-
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
COMPLETED · Phase 4
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia